SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Overview | Financials
Company Name | SELLAS Life Sciences Group, Inc. |
Symbol | SLS |
Currency | USD |
Price | 0.95 |
Market Cap | 66,891,053 |
Dividend Yield | 0% |
52-week-range | 0.5 - 1.72 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Angelos M. Stergiou M.D., ScD h.c. |
Website | https://www.sellaslifesciences.com |
An error occurred while fetching data.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD